Evidence map›Paper›PMID 42812954›Full record

ArticleFrontiers in bioengineering and biotechnology2026

Chitosan-coated mesoporous silica nanoparticles for pH-responsive doxorubicin delivery in head and neck cancer.

Andrej Jenča, Elham Saberian, Janka Jenčová, Adriána Petrášová, Andrej Jenča, Hadi Zare-Zardini, Olexandr Kurmyshov, Naďa Homzová, Kornélia Pandyová, Mária Futejová and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Andrej JenčaClinic of Stomatology and Maxillofacial Surgery, Academy of Košice, Pavol Jozef Šafárik University, Košice, Slovakia.
Elham SaberianClinic of Stomatology and Maxillofacial Surgery, Academy of Košice, Pavol Jozef Šafárik University, Košice, Slovakia.
Janka JenčováClinic of Stomatology and Maxillofacial Surgery, Academy of Košice, Pavol Jozef Šafárik University, Košice, Slovakia.
Adriána PetrášováClinic of Stomatology and Maxillofacial Surgery, Academy of Košice, Pavol Jozef Šafárik University, Košice, Slovakia.
Andrej JenčaClinic of Stomatology and Maxillofacial Surgery, Academy of Košice, Pavol Jozef Šafárik University, Košice, Slovakia.
Hadi Zare-ZardiniDepartment of Biomedical Engineering, Meybod University, Meybod, Iran.
Olexandr KurmyshovClinic of Stomatology and Maxillofacial Surgery, Academy of Košice, Pavol Jozef Šafárik University, Košice, Slovakia.
Naďa HomzováClinic of Stomatology and Maxillofacial Surgery, Academy of Košice, Pavol Jozef Šafárik University, Košice, Slovakia.
Kornélia PandyováClinic of Stomatology and Maxillofacial Surgery, Academy of Košice, Pavol Jozef Šafárik University, Košice, Slovakia.
Mária FutejováClinic of Stomatology and Maxillofacial Surgery, Academy of Košice, Pavol Jozef Šafárik University, Košice, Slovakia.
Azadeh EmamiTraditional Pharmacy and Pharmaceutical Sciences Research Center, and Department of pharmaceutics, Faculty of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Mohsen Nabi MeybodiTraditional Pharmacy and Pharmaceutical Sciences Research Center, and Department of pharmaceutics, Faculty of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Head and neck squamous cell carcinoma (HNSCC) is among the most common cancers worldwide. Despite therapeutic advances, patient survival remains low due to recurrence, metastasis, and the severe side effects of conventional chemotherapy. Doxorubicin (DOX) is an effective drug; however, its cardiotoxicity and non-specific distribution limit its clinical use. This study aimed to design a pH-sensitive smart nanocarrier based on chitosan-coated mesoporous silica nanoparticles (MSN-DOX@CS) for targeted DOX release in the acidic tumor environment. Methods: The nanoparticles were synthesized by the sol-gel method and coated with chitosan. Physicochemical characteristics (FESEM, DLS, FTIR), drug release at pH 7.4 and 5.5, and cytotoxicity (MTT) on HNSCCs were evaluated. Results: The results showed that the nanoparticles are semi-spherical (∼145 nm) with a positive surface charge (+28.6 mV). Drug release at blood pH was only 18%, while at tumor pH it exceeded 76%. The empty nanocarrier was non-toxic (>90% cell survival), and the drug-loaded version exhibited greater toxicity than the free drug at 48 h ( Discussion: In conclusion, MSN-DOX@CS is presented as a safe and effective platform for targeted chemotherapy of HNSCC, with reduced systemic side effects and increased intracellular efficacy.

Indexed as

chitosandoxorubicinhead and neck squamous cell carcinomapH-sensitivesilica nanoparticles

Identifiers

PMID42812954
PMCPMC13621281

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.